Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease

  1. Maria-Christina Kyrtsonis,
  2. Theodoros P. Vassilakopoulos,
  3. Marina P. Siakantaris,
  4. Styliani I. Kokoris,
  5. Despina A. Gribabis,
  6. Maria N. Dimopoulou,
  7. Maria K. Angelopoulou,
  8. Gerassimos A. Pangalis

Article first published online: 8 MAR 2004

DOI: 10.1046/j.0902-4441.2003.00205.x

Issue

European Journal of Haematology

European Journal of Haematology

Volume 72, Issue 4, pages 252–258, April 2004

Additional Information

How to Cite

Kyrtsonis, M.-C., Vassilakopoulos, T. P., Siakantaris, M. P., Kokoris, S. I., Gribabis, D. A., Dimopoulou, M. N., Angelopoulou, M. K. and Pangalis, G. A. (2004), Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. European Journal of Haematology, 72: 252–258. doi: 10.1046/j.0902-4441.2003.00205.x

Author Information

  1. Hematology Section and Research Laboratory, First Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece

*Gerassimos A. Pangalis, MD, National and Kapodistrian, University of Athens School of Medicine, Hematology Section, First Department of Internal Medicine, Laikon General Hospital, 16 Sevastoupoleos St., Athens 11526, Greece Tel: 30-201-7719744 Fax: 30-201-6928249 e-mail: pangalis@otenet.gr

Publication History

  1. Issue published online: 8 MAR 2004
  2. Article first published online: 8 MAR 2004
  3. Accepted for publication 3 December 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (201K)

Keywords:

  • multiple myeloma;
  • VEGF;
  • bFGF;
  • serum syndecan-1;
  • serum metalloproteinase-9;
  • serum osteoprotegerin

Abstract:

Neovascularisation and bone resorption are related to myeloma disease activity.

Objectives:  To investigate the possible prognostic importance of serum syndecan-1, basic fibroblast growth factor (bFGF) and osteoprotegerin (OPG) levels, the relationship between them, with parameters of disease activity and the effect of treatment on their levels.

Patients and Methods:  Twenty-seven patients were studied from diagnosis and an additional five from remission, for a median follow-up of 40 months. Twenty-three patients received chemotherapy plus bisphosphonates and nine only bisphosphonates. Sera from 11 healthy individuals (HI) were used as controls. Cytokines were determined by commercially available enzyme-linked immunosorbent assays (ELISA) kits.

Results:  In HI, median syndecan-1 was 40 ng/mL (28–75), bFGF 8 pg/mL (7–30), OPG 35 pg/mL (4–100). Pretreatment median serum syndecan-1 was 177.5 ng/mL (34–3500), bFGF 11.5 pg/mL (8–65) and OPG 100 pg/mL (4–1000). Pretreatment syndecan-1, bFGF and OPG serum levels were increased in patients compared with HI (P = 0.001, 0.03 and 0.01, respectively). Syndecan-1 and bFGF levels were correlated with stage (P = 0.004 and 0.03, respectively). Both syndecan-1 and OPG levels were correlated with β2M (P = 0.04 and 0.01, respectively). Patients with elevated syndecan-1 and bFGF serum levels had shorter survival than patients with normal levels (P = 0.01 and 0.05, respectively). After chemotherapy syndecan-1 and OPG levels were found to be decreased in responders and syndecan-1 level was reduced in patients receiving bisphosphonates alone.

Conclusions:  Pretreatment syndecan-1, bFGF and OPG levels were found to be increased at diagnosis. Syndecan-1 and OPG fluctuated according to MM activity. Elevated serum syndecan-1 and bFGF levels predicted short survival.

View Full Article (HTML) Get PDF (201K)